ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-CD44v9 Antibody-drug Conjugate AMT-116

Also written as “AMT-116” and “AMT-116 CAR-T cells”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Melanoma, led by 2 companies.

Drug pageAnti-CD44v9 Antibody-drug Conjugate AMT-116: every studyAll 5 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jul 13, 20265 company-led studies, 4 open or runningNext primary completion: Dec 30, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Multitude Therapeuticsits history only44 open or runningphase 3since Jul 13, 2026Feb 2, 2023Dec 30, 2026phase 1 · NCT05725291
Imunopharm Technologyits history only10 open or runningphase 2since Sep 6, 2021Sep 6, 2021none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of every company. Pick one to see its own:

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 6, 2021First study: phase 2 study in MelanomaNew to Imunopharm TechnologyImunopharm Technology · NCT05117138 · 39 enrolled · China
  2. Feb 2, 2023Multitude Therapeutics’ first study: phase 1 study in Advanced Solid TumorNew to Multitude TherapeuticsMultitude Therapeutics · NCT05725291 · 80 planned · United States, American Samoa, Australia
  3. Dec 20, 2024Phase 2 study in Advanced Solid TumorsMultitude Therapeutics · NCT06782334 · 144 planned · China
  4. May 10, 2026Phase 2 study in Advanced Non-small Cell Lung Cancer (NSCLC)Multitude Therapeutics · NCT07590531 · 118 planned · China
  5. Jul 13, 2026Phase 3 study in Carcinoma, Non-Small-Cell LungPhase 3 reachedMultitude Therapeutics · NCT07718737 · 512 planned · United States, Australia

Ahead

  1. Dec 30, 2026Primary completion: phase 1 study in Advanced Solid TumorMultitude Therapeutics · NCT05725291
  2. May 30, 2027Primary completion: phase 2 study in Advanced Non-small Cell Lung Cancer (NSCLC)Multitude Therapeutics · NCT07590531
  3. Mar 30, 2028Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungMultitude Therapeutics · NCT07718737

TargetBeta

CD44 →read by rule
“An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) CD44 variant 9 (CD44v9), ”NCIt, by rule

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07718737Carcinoma, Non-Small-Cell Lung · United States, Australia3RecruitingMultitude TherapeuticsMar 30, 2028512
NCT07590531Advanced Non-small Cell Lung Cancer (NSCLC) · China2RecruitingMultitude TherapeuticsMay 30, 2027118
NCT06782334Advanced Solid Tumors · China2RecruitingMultitude TherapeuticsJun 30, 2026144
NCT05725291Advanced Solid Tumor · United States, American Samoa, Australia1RecruitingMultitude TherapeuticsDec 30, 202680
NCT05117138Melanoma · China2UNKNOWNImunopharm TechnologyDec 1, 202339

How it is read

Names in the registry

  • “AMT-116”, 4 entries
  • “AMT-116 CAR-T cells”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.